Skip to main content

Japan to make COVID-19 travel questionnaire available online

By Unknown

Japan will make available an online version of a health questionnaire that travelers are required to fill out before entering the country to streamline the immigration control process, sources familiar with the matter said Saturday.

The online questionnaire meant to flag travelers who are possibly at higher risk of arriving while infected with the coronavirus will be available soon on a trial basis for some international flights arriving at Narita airport near Tokyo, they said.

The questionnaire is currently handed out to travelers aboard inbound flights.

With the new system to be introduced more widely later this year, arriving passengers can complete the questionnaire by accessing a dedicated website of the Health, Labor and Welfare Ministry before their departure and are given a QR code that confirms they have completed the process to use upon arrival, according to the sources.

Japanese authorities said Friday the country will reopen its borders to foreigners with permits to stay for three months or longer for purposes including engaging in medical, cultural and sports-related activities. Business trips for less than three months will also be allowed.

Travelers must be accepted by entities or organizations capable of ensuring they have tested negative for the virus before entering Japan. After arrival, they have to stay in self-isolation for 14 days and avoid using public transportation during the period.

The government is considering limiting the number of entries to about 1,000 each day. At the same time, it will increase virus testing capacity at airports, government sources said earlier.

The number of infections in the country has been on a downward trend since late July, although the pace of decline has been slowing recently and has bottomed out in Tokyo, according to an advisory group for the health ministry.

More than 630 new cases were reported nationwide Saturday, up from 575 Friday, bringing the cumulative total to over 82,400, including about 700 cases from the Diamond Princess, a cruise ship that was quarantined in Yokohama in February.

Tokyo, the hardest-hit area among the country's 47 prefectures, confirmed 270 new infections the same day, up from 195 the previous day. The capital reported 59 cases, its lowest daily figure in nearly three months, on Wednesday.

Japan currently imposes an entry ban on 159 countries and regions. Foreigners who have been to any of the places within 14 days of their arrival are being turned away, with some exceptions.

The government has started gradually rolling back its travel restrictions. Foreigners with resident status in Japan who had traveled outside the country have been allowed re-entry from September.

Expatriates and other long-term residents have been allowed to come from some Asian countries, including Vietnam and Thailand. Foreign students on government grants can also enter the country.

Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Glenmark's antiviral combination for moderate Covid-19 shows no clinical benefit

By Unknown
Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points,  the company said. The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China. Fujifilm last month said a late-stage study of Avigan showed i...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more